Ferring has been developing treatments for mothers and babies for over 50 years. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Company Overview: Ferring pharmaceuticalsįerring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Microbiome: Company and Product Profiles (Marketed Therapies)ġ. The agreement pairs Federation Bio’s proprietary ACTT (anerobic co-culture technology) platform with the expertise and capabilities of MD Anderson’s Platform for Innovative Microbiome and Translational Research (PRIME-TR). In February 2023, The University of Texas MD Anderson Cancer Center and Federation Bio, a biotechnology company pioneering bacterial cell therapies, announced a strategic collaboration to design and manufacture a complex, synthetic microbial consortium with the goal of expanding the number of cancer patients who respond to immunotherapy. will leverage Holobiome’s platform to identify, isolate, and develop next-generation probiotic bacteria and the prebiotics that help them flourish. The research collaboration with Johnson & Johnson Consumer Inc. The collaboration is the latest in a string of collaboration deals between the two companies, and marks Holobiome’s first foray into the arena of the early-life microbiome. to develop next-generation probiotics and prebiotics, aimed at supporting infant and maternal immune health. In March 2023, Holobiome announces research collaboration with Johnson & Johnson Consumer Inc.
#4D PHARMA IBS SKIN#
The collaboration will focus on developing new methods for non-invasive genomic-based skin testing, to help Sequential add to their growing database of skin samples.
(“Sequential”), the skin microbiome company developing next generation non-invasive skin testing and data-driven solutions for the skin microbiome, announced that it has entered into a collaboration agreement with Johnson & Johnson Consumer Inc. ADM is leveraging Brightseed’s artificial intelligence (A.I.) platform, Forager, to decipher the molecular interactions between dietary plants and gut microbes, and their potential impact on human health. In April 2023, ADM, a global leader in nutrition that powers many of the world’s top food, beverage, and health and wellness brands, and Brightseed, the bioactives company and a World Economic Forum Global Innovator, announced a global joint partnership to develop evidence-based functional synbiotic products that target microbiome optimization with an undisclosed investment. It further highlights the inactive pipeline products in this space. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. This “Microbiome- Competitive landscape, 2023” report provides comprehensive insights about 130+ companies and 180+ drugs in Microbiome Competitive landscape. DUBLIN–(BUSINESS WIRE)–The “Microbiome – Competitive landscape, 2023” report has been added to ’s offering.
0 kommentar(er)
